The Uromigos

Brian, Tom and Silke discuss their highlights form ASCO 2025

Josh Meeks joins us to give stellar overview of the emerging data in this space. We also discuss the recent ODAC ruling for lower risk patients.

Gert Attard joins us to discuss this practice-changing data and the highlight of ASCO 2025

Nick James discusses intriguing data from STAMPEDE to us AI to analyze pathology slides to predict benefit from ADT + abiraterone

Jorge Garcia joins us to discuss the process of selecting abstracts for oral presentation and select highlights from this session.

Toni Choueiri discusses this combination cohort of HIF inhibition plus VEGF-R inhibition.

Matt Galsky discusses the ASCO 2025 data regarding ctDNA from the NIAGARA neoadjuvant chemo +/- durvalumab study.

Jeannie Hoffman-Censits discusses her randomized phase 2 adding SG to maintenence avelumab in mUC.

Michiel Van Der Heijden joins us to discuss the Ipi/Nivo vs chemo randomization in this trial from his ASCO 2025 presentation

Monty Pal discusses more correlates from this trial including matched baseline and progression tissue samples.

David McDermott joins us on the heels of his outstanding discussion of the clinical science symposium on RCC biomarkers.

Practice Changing?  独断と偏見で選んだ注目演題について結果の予想も含めて議論しました。

Silke, Tom and Brian discuss what they are looking forward to at ASCO 2025

日本と海外の違いはあるのか？mHSPCとmCRPCのUromigos Scoreについて激論！！

Edición especial en castellano con Alfonso Gómez de Liaño y Guillermo de Velasco. David Lorente da su visión sobre el nuevo Uromigos Score, que clasifica distintas opciones de tratamiento en varios escenarios de cáncer de próstata metastásico

Silke and Chris joins us to discuss our latest 'Uromigos Score' in which experts score the value of treatments for advanced prostate cancer. Several interesting themes emerge.

Mark Tyson from Mayo Clinic joins the podcast to discuss this replicating adenovirus and a high CR rate in BCG-unresponsive NMIBC

Joe Jacob joins the show to discuss the longer-term follow up of this cohort from SunRISe-1. We discuss definitions of CR and regulatory issues around drug approval in this space as well.

Viktor Grunwald joins to discuss the new data session from EIKCS

Mark Tyson from Mayo Clinic joins the podcast to discuss this replicating adenovirus and a high CR rate in BCG-unresponsive NMIBC

Neal Shore joins the show to discuss these exciting data from the American Urological Association Annual Meeting

今月Eur Urol OncolにPublishされたヨーロッパのエキスパートによるmRCCのコンセンサスについて日本との違いについて深い議論をしました！！

Part 2 of our series dives deeper into the explosion of ADC clinical drug development in China

Drs. Dingwei Ye and Yao Zhu from China join the show to talk about drug development in China amid the recent surge of GU clinical trials.

Drs. Alicia Morgans and Chuck Ryan join the show to talk about their new podcast.

Elena Castro joins Tom and Brian on the day after Pluvicto approval pre-chemotherapy in the US to discuss the PSMA Fore data and application in clinical practice.

Ignacio Duran continues his discussion with Brian and Tom regarding novel ADCS in bladder cancer

Cristina Suárez analiza los próximos ensayos clínicos que podrían transformar el manejo del cáncer renal en los próximos años: nuevas combinaciones adyuvantes y estrategias perioperatorias, el uso de tripletes enprimera línea y la integración de inhibidores de HIF con TKIs, entre otros.

Ignacio Duran joins the show to discuss the landscape of established ADCs in urothelial cancer and challenges of drug development in this setting.

Live from the Canary Islands 'Big Idea' talk from Tom, we discuss the new Uromigos Score which ranks different treatment options in several urothelial cancer settings.

Dr. John Heymach from MD Andersons joins us to discuss a novel PD1/VEGF bispecific agent in lung cancer and if there are applicaitons in GU malignancies.

Chuck Ryan joins us to discuss his interview with Felix and reflects on his keynote address at ASCO GU 2025.

Silke Gillessen joins us to discuss the top areas of consensus and controversy from APCCC 2025

尿路上皮癌と腎癌の臨床に影響を与えるエビデンスをどう解釈するか!?

ASCOGU2025で発表された臨床試験の結果の解釈について忖度なしに議論しました！！

Tyler Seibert from UCSD joins the show live from Lugano to discuss meeting highlights and controversies (and his favorite run along the water..)

Silke joins Tom and Brian to discuss highlights form ASCO GU 2025

Toni Choueiri discusses the updated data from different cohorts of this novel HIF inhibitor.

Vincent Xu discusses this emerging RCC biomarker and data from the Checkmate 214 trial

Laurence Albiges joins the show to discuss novel combos in refractory RCC and an update of the Ipi/Nivo/Cabo COSMIC OS data

Gopa Iyer from MSKCC joins the show to discuss his initial results from this phase 2 trial.

Xinan Sheng. M.D., Professor in the Department of Genitourinary Oncology at Peking University Cancer Hospital &institute in Beijing, China joins us to discuss the update of this trial and impressive pCR rates.

Matt Galsky joins the show to discuss pCR in NIAGARA and clinical implications.

Tanya Dorff from City of Hope joins us to discuss clinical implications of these data and also comment on TALAPRO-2

Neeraj Aggarwal joins Tom and Brian for an in-depth look at these important data

Silke Gillessen joins Brian and Tom and they discuss what to look forward to in prostate, bladder and RCC at ASCO GU 2025.

David Braun joins the show to discuss his Nature paper on a personalized RCC vaccine

残念ながらNegative StudyとなったTROPICs-04についてUromigos Japanの3人が忖度なしに、その原因や理由について考察をします！！

Romain Banchereau joins the show to discuss and debate this Cancer Cell paper on molecular subtypes in urothelial cancer and implications for checkpoint blockade.

Shankar Siva joins the show to discuss the emerging role of stereotactic body radiotherapy (SBRT) in primary and metastatic RCC tumors.

3人による2024年のGU oncoloyのレビューを切れ味鋭く解説しています。乞うご期待！